Amgen's (AMGN) Buy Rating Reaffirmed at Goldman Sachs Group Inc.

Amgen's (AMGN) Buy Rating Reaffirmed at Goldman Sachs Group Inc.


's stock had its "buy" rating reiterated by analysts at Goldman Sachs Group Inc. in a research note issued to investors on Tuesday. They presently have a $206.00 price target on the medical research company's stock, up from their prior price target of $204.00.



from Biotech News